Learn more about the science from our team and other industry experts.
"In the overall sample, 17 participants (71%) atweek 1 and 17 (71%) atweek 4 had a clinically significant response to the intervention (_50% reduction in GRID-HAMD score), and 14 participants (58%) atweek 1 and 13 participants (54%) atweek 4were in remission (_7 GRID-HAMD score)."
"Within-group effects at post-treatment and six-month follow-up showed large reductions in anxiety and depression symptoms with no evidence of publication bias. Qualitative assessment of risk of bias was more concerning, with high risk in several domains. High between-study heterogeneity suggests there may be systematic variation across the studies. Future meta-analyses should examine study features (e.g., psilocybin dose) as moderators of treatment effects. Effects of psilocybin on anxiety and depression were also evident."
The current study is the first qualitative study of participant experiences in psilocybin-assisted psychotherapy. Participants received a moderate dose of psilocybin and adjunctive psychotherapy with an emphasis on the process of meaning-making. The findings support the conclusion that psilocybin-assisted psychotherapy may provide an effective treatment for psychological distress in cancer patients.Implications for theory and treatment are discussed.
Clinically significant anxiety and depression are common in patients with cancer, and are associated with poor psychiatric and medical outcomes. Historical and recent research suggests a role for psilocybin to treat cancer-related anxiety and depression. In conjunction with psychotherapy, single moderate-dose psilocybin produced rapid, robust and enduring anxiolytic and anti-depressant effects in patients with cancer-related psychological distress.